Valneva wants short-term travel, too, for JE vaccine Ixiaro
This article was originally published in Scrip
While a US federal panel last week unanimously backed the use of Valneva's Ixiaro in youngsters and adolescents to protect against Japanese encephalitis (JE), which can be deadly, the committee's recommendation was limited, with the experts declaring the vaccine need not be considered for short-term travelers whose visits will be restricted to urban areas of countries in which the mosquito-borne flavivirus is endemic or times outside of a well-defined transmission season.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.